Podcasts about cellectis

Auriane Cano-Chancel, la patronne de l'oncologie chez AstraZeneca France, revient tout juste du congrès de l'ASCO 2024 à Chicago. Elle partage avec enthousiasme les dernières avancées et innovations dans le cancer, illustrant l'impact significatif des nouvelles thérapies sur la vie des patients.Auriane nous raconte son parcours atypique, de l'Armée de l'Air à Polytechnique, à son rôle actuel chez AstraZeneca. Son expérience diversifiée démontre l'importance de l'adaptabilité et de la passion dans la poursuite de l'excellence en médecine.Pour nous expliquer l'épopée d'innovation que vit cette entreprise en ce moment, elle partage comment Pascal Soriot, CEO d'AstraZeneca, a su identifier et investir dans des molécules prometteuses, même quand d'autres les considéraient comme trop risquées. Sa vision stratégique et son audace ont transformé l'entreprise, plaçant l'innovation au cœur de ses priorités.Enfin, Auriane aborde la complexité d'être un leader et un modèle sur un marché en constante évolution. Elle souligne l'importance de la confiance, de la collaboration et de l'innovation pour inspirer et guider ses équipes vers des succès durables.Auriane met en avant le rôle crucial de l'exemplarité et de la vision stratégique pour rester à la pointe dans un secteur compétitif. En combinant rigueur scientifique et management humain, elle démontre comment un leadership éclairé peut transformer les défis en opportunités.Cet épisode est réalisé avec le soutien d'AstraZeneca laboratoire expert en oncologie, cardiologie, métabolisme et maladies rares. -Notes et références de l'épisodeEntreprises citées : Astra Zeneca : https://www.astrazeneca.fr/Cellectis : https://www.cellectis.com/Daiichi Sankyo : https://www.daiichisankyo.com/IPSEN : https://www.ipsen.com/france/LEK : https://www.lek.com/Personnalités citées : Marc de Garidel : https://smartlink.ausha.co/pharma-minds/marc-de-garidel-ceo-abivax-take-risks-to-build-something-meaningfulKarine Levesque : https://smartlink.ausha.co/pharma-minds/karine-levesque-gm-csl-vifor-france-l-authenticite-de-rebondir-pour-reussirPascal SoriotHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

C'était bien hier, ce sera mieux demain. À l'occasion des 70 ans de l'Express, nous avons interrogé des personnalités, entrepreneurs, experts pour esquisser le futur de notre monde, dans 70 ans. Dans ce nouvel épisode de notre podcast intitulé 2093, le journaliste Antoine Perrin a rencontré André Choulika, co-fondateur de Cellectis, une biotech française pionnière dans l'édition d'un gène permettant le développement de thérapies nouvelles.Retrouvez tous les épisodes sur le site de l'Express Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Dans ce nouveau numéro du Journal des biotechs, Frédéric Gomez revient sur l'actualité de Valneva, Gensight et nous fait découvrir une pépite de la médecine nucléaire : Eckert & Ziegler.L'entretien est consacré à André Choulika, PDG de Cellectis qui revient sur le deal stratégique conclu avec AstraZeneca et sur les développements en cours dans les CAR-T allogéniques, notamment UCART-22.

Dans ce numéro du Journal des biotechs, Jamila El Bougrini, analyste chez Invest Securities revient sur l'actualité récente ou à venir de Cellectis, Abivax et Genfit.L'entretien est consacré à Frédéric Cren, PDG d'Inventiva. Il revient sur l'accord récent conclu avec le groupe japonais Hepalys Pharma qui vient compléter son maillage asiatique. Il fait également le point sur les essais en cours avec Lanifibranor, l'état de la concurrence dans la Nash et la trésorerie de la société.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## Health AI startup Olive is shutting down. The company, once valued at $4 billion, has struggled due to high costs and the failure to secure new funding. This news is a blow to the digital health industry, which has seen a boom in funding recently. ## On another note, Doctors' Management Services has settled claims with the US Department of Health and Human Services (HHS) regarding a ransomware attack that exposed patient information. This settlement marks the first time HHS has taken action against a company for failing to comply with breach notification rules under HIPAA. ## President Joe Biden has issued an executive order for HHS to collect reports on the safety of healthcare AI. This move is part of a larger effort to ensure "safe, secure, and trustworthy" artificial intelligence in healthcare. ## Lastly, Kaiser Permanente has reached a tentative contract deal with a labor union in Washington, preventing a strike by 3,000 workers scheduled for November 1.## In other news, British biopharmaceutical company GSK has reported a 10% increase in sales in the third quarter. This growth can be attributed to strong sales of their respiratory syncytial virus shot Arexvy and shingles vaccine Shingrix. As a result, GSK has raised its outlook for the year.## The US Food and Drug Administration's advisory committee has determined that the off-target analysis for Vertex Pharmaceuticals and CRISPR Therapeutics' sickle cell disease candidate, ExA-Cel, is sufficient.## Astrazeneca has invested $245 million in French biotech firm Cellectis as part of their ongoing efforts to advance cell and gene therapy development. This investment caused Cellectis shares to increase by over 180% in premarket trading.## And finally, a webinar will be held to discuss the optimization of biomarker assays to bridge the gap in clinical trial participation. The use of multiplexed patient-centric assays could help reduce the burden on patients.That's all for today's episode. Stay tuned for more important news in the Pharma and Biotech world.

Good morning from London where the FTSE 100 is up once again this morning ahead of today's big interest rate call over in the US. Most of big stories coming out of the UK this morning are company earnings, and Aston Martin shares are down 10% on the day after the luxury car maker scaled back its full-year volume guidance on production issues with the DB12. GSK has had a more positive start, highlighted strong sales of its respiratory virus vaccine Arexvy as a factor in good third-quarter results. Retailer Next also rose early on too, lifting its full-year profit guidance on stronger-than-anticipated sales in the three months to October. Outside of this morning's earnings announcements AstraZeneca has announced a partnership with French firm Cellectis which will see the pair work together on gene therapies. Nationwide are reporting that average UK property prices had rose by 0.9% between September and October. #ProactiveInvestors #FTSE100 #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this episode, we speak with André Choulika about his exciting journey from a bench scientist to a biotech entrepreneur taking genomic engineering to the clinicAndré shares his fascination about the logic of biological systems and his admiration for experimentalists“You can always do something else if it fails” insists AndréAndré stresses that the boss has to take responsibilities for decisions“You don't hire people to tell them what to do, but they should tell you what needs to be done”“Cash is more important than your mother”(we hope Andre's mother isn't listening)“Success has thousands of fathers but failure is lonely” (lonelier than a pipette!)André is modest about success; “None of us are VIPs” and he insists that the people who wash the dishes are as important as the CEO of the companyHe describes the collective contributions and the shared success that characterize the biotech industry For André “Leadership is more important than management”He insists that a successful meeting is one than lasts less time than allocatedHe mentioned these labs, scientists, institutions and companiesRichard Mulligan : https://genetics.hms.harvard.edu/faculty-staff/richard-charles-mulliganInstitut Pasteur : https://www.pasteur.fr/enMaxime Schwartz : https://en.wikipedia.org/wiki/Maxime_SchwartzMargaret Buckingham : https://en.wikipedia.org/wiki/Margaret_BuckinghamHEC Business School : https://www.hec.edu/enNew England Biolabs (NEB) : https://international.neb.com/Steve Jobs : https://en.wikipedia.org/wiki/Steve_JobsBernard Dujon : https://en.wikipedia.org/wiki/Bernard_DujonTo find out more about André visit his website and his companies :https://en.wikipedia.org/wiki/Andr%C3%A9_Choulikahttps://www.linkedin.com/in/choulika/Cellectis : https://cellectis.com/enCalyxt : https://calyxt.com/To find out more about Renaud :Twitter : https://twitter.com/LePourpreLinkedIn : https://www.linkedin.com/in/renaudpourpre/To find out more about Jonathan :Twitter : https://twitter.com/EpigenetiqueLinkedIn : https://www.linkedin.com/in/jonathanweitzman/%20To learn more about the soundtrack :Music by Amaria - Lovely Swindlerhttps://soundcloud.com/amariamusique/https://twitter.com/amariamusique

While the emergence of CAR-T therapies have been promising, these autologous cellular therapies are costly to produce since they require taking T cells from a patient being treated, altering them, and then infusing them back into the patient. Cellectis is among a growing list of companies pursuing off-the-shelf CAR-T therapies. The company's U-CARTs, or universal chimeric antigen receptor T cells, are allogenic products that can be standardized and carry both time and cost advantages. We spoke to André Choulika, CEO of Cellectis, about the company's off-the-shelf CAR-T therapies, the platform technology behind them, and its programs in development.

Cellectis' decision to build and operate its own trans-Atlantic manufacturing facilities was a strategic one. On this week's episode of the Business of Biotech, SVP of U.S. Manufacturing Steve Doares talks  internal manufacturing rationale, discusses interoperability between its Paris and Raleigh, N.C. plants, and shares how the company keeps meeting the challenges presented by COVID-fueled supply chain disruptions head-on. 

In dieser Podcastepisode schilderte André Choulika, CEO von Cellectis, auf dem 17. 2b AHEAD Zukunftskongress die neuen Möglichkeiten der Genetik für die nächsten zehn Jahre.Er prognostiziert: Durch Genome Editing wird es in Zukunft möglich sein, unseren DNA Code sowohl neu- als auch umzuschreiben und somit alle im Menschen genetisch verankerten Begrenzungen aufzuheben. Choulika spricht vom Update des Humangenoms und einem Übergang des Sapiens 1.0 zu einer neuen menschlichen Zelle, die keine Mutationen mehr aufweisen wird. Werden wir so in baldiger Zukunft die gefährlichsten Menschheitskrankheiten wie zum Beispiel Krebs endgültig besiegt haben?Für Andé Choulika steht fest: Der Mensch wird sich selbst upgraden und zum Programmierer des Lebens entwickeln. In Zukunft wird es ihm sogar möglich sein, mithilfe von Technologien der Bioinformatik, Sequenzierung und Robotertechnik, komplett neue  Lebensformen zu erschaffen sodass innerhalb der nächsten Jahrzehnte wohlmöglich schon künstliche Organismen unseren Planeten besiedeln werden.______________________________________Wenn du mehr erfahren willst, besuche auch meine Website: https://janszky.de/?p und abonniere diesen Kanal.Hier geht's zum 2b AHEAD Zukunftskongress: https://zukunftskongress.2bahead.com/?pWerde zum Future-Me Member: https://janszky.de/futureme_membership?pSichere Dir jetzt Dein Geschenk auf: https://janszky.de/geschenk?p

When Caribou Biosciences (NASDAQ: CRBU) became the seventh publicly-traded CRISPR stock in July 2021, I saw an exchange on social media. One person asked why the company sported a market valuation of $900 million when another newly-public CRISPR stock, Verve Therapeutics (NASDAQ: VERV), was valued near $2.3 billion. "Is there any reason for this other than the timing of the IPOs?", asked the individual. The thread received multiple responses confirming the seemingly large valuation difference between the two companies, with others "agreeing" or responding that they were buying Caribou Biosciences because of it. That was 100% the wrong take. I've observed similar arguments among individual investors within the gene editing space. However, it's important to acknowledge that there are significant differences between gene editing approaches and technology platforms. Caribou Biosciences and Verve Therapeutics might both be using CRISPR systems, but that's where the overlap ends. They're developing completely different tools that have almost nothing in common. Individual investors don't necessarily need to have a deep technical understanding of gene editing tools, but I would argue that there's a minimum level of information required to responsibly invest in the field. Unfortunately, the way the internet works means most investors aren't provided with the information they need. Let's fix that. In this episode of the podcast, 7investing Lead Advisors Maxx Chatsko (me) and Dan Kline introduce simple frameworks for evaluating opportunities and challenges in gene editing. These can be summarized as follows: The Emerging Approaches: There's first-generation tools (gene editing), second-generation tools (base editing), and third-generation tools (prime editing). These approaches are not limited to any specific system. For example, there are CRISPR, TALEN, ARCUS, and other tools capable of performing base editing. The Major Applications: There are knock outs, insertions, activations, precise corrections, knock ins, and other uses of gene editing tools. Each has advantages and disadvantages. The Major Administration Routes: This primarily comes down to in vivo (inside the body) and ex vivo (outside the body). Each has advantages and disadvantages. In addition to this podcast introducing the three frameworks, 7investing Lead Advisor Maxx Chatsko has written an in-depth article explaining these frameworks and how each gene editing stock fits into each -- and it's free to read! Publicly-traded companies mentioned in this podcast include Alnylam Pharmaceuticals, Beam Therapeutics, Caribou Biosciences, Cellectis, CRISPR Therapeutics, Editas Medicine, Graphite Bio, Intellia Therapeutics, Precision BioSciences, Sana Biotechnology, and Verve Therapeutics. 7investing Lead Advisors may have positions in the companies that are mentioned. This interview was originally recorded on August 2nd, 2021 and was first published on August 3rd, 2021. --- Send in a voice message: https://anchor.fm/7investing/message Support this podcast: https://anchor.fm/7investing/support

The first chimeric antigen T-Cell Therapy (CAR-T) therapies were approved by the Federal Drug Administration (FDA) in 2017--these were heralded as “cures” for blood-borne cancers such as acute myeloid leukemia and aggressive non-Hodgkin’s Lymphoma. Here, we have Simon Harnest, the Senior Vice President of Corporate Strategy and Finance of Cellectis (CLLS), unpacking where cell therapy is headed towards. Cellectis is the first company  to envision an “off-the-shelf” approach to CAR-T therapy. Previous methods required long manufacturing times and complex methodologies to create a single treatment for a patient. In this episode, Simon guides us through the complexities of creating an allogeneic approach for developing CAR-T therapies, especially for solid tumors, and addresses why Cellectis is up for the challenge. He also addresses the discrepancy between current valuations of Cellectis and competitor, Moderna (MRNA) who happens to license from Cellectis. This podcast is for anyone interested in learning about the nitty gritty of next generation cancer care from the bottom-up perspective. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $17 per month. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investingofficial --- Send in a voice message: https://anchor.fm/7investing/message

pomeさんをゲストに迎え、TALEN・UCART治療・シングルセル解析・核酸医薬・DNA合成に関する技術と関連のバイオテック企業の動向について話を伺いました。Shownotes Researchat.fm ep79…pomeさんゲスト回前編はこちらです。 TALEN…詳しくはResearchat.fm ep76 Cellectis … Swedenではなく、Franceの企業だったようです。(BB氏訂正ありがとうございました。) CAR-T UCART…Universal Chimeric Antigen Receptor T-cells。”Off-the-shelf”ってかっこいいですね。 T細胞 (Wikipedia) HLA (Wikipedia) NK細胞 (Wikipedia) CD47 (Uniprot) Pfizer Allogene Therapeutics CRISPR (Wikipedia)…Researchat.fmの過去回をお聞きください。Researchat.fm ep76、Researchat.fm ep77など iPS細胞 (Wikipedia) Spatial Transcriptomics 10X Genomics seqFISH FACS (Wikipedia) BioLegend Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell 2015…InDrop法による１細胞シングルセル解析の元論文 1CellBio Broad Institute アンチセンスRNA 筋ジストロフィー (Wikipedia) 核酸医薬 (Wikipedia) siRNA (Wikipedia) 固相合成 (Wikipedia) 液相合成 T7 (NEB) GenScript TdT (Wikipedia) … 話が途中からDNA合成からRNA合成にすり替わってしまいましたが、RNA合成の基本であるIVT(in vitro transcription)に関してはまたいつか話します。 Molecular Assemblies, Inc Enzymatic DNA synthesis enters new phase. Nature Biotech 2020…TdTを用いたDNA合成の最前線に関する記事(2020/10月) De novo DNA synthesis using polymerase-nucleotide conjugates. Nature Biotech 2018…TdTを用いた核酸合成の元論文。 Moderna…今COVID-19のワクチンで名前を轟かせている製薬会社 さくら通信 さくら剛 (Wikipedia) インドなんて二度と行くか!ボケ!!―…でもまた行きたいかも (Amazon) 感じる科学 (Amazon) 丸山ゴンザレス (Wikipedia) … 通称丸ゴンさん 海外ブラックロード … 丸ゴンさんと嵐よういちさんのポッドキャスト 丸山ゴンザレスの裏社会ジャーニー (Youtube) クレイジージャーニー (Wikipedia) 草下シンヤ … 個人的には草下さんも超気になっている。まさか裏のハローワークの作者だったのか… BLUE GIANT (Amazon) Editorial notes ブルージャイアント読者仲間がいて嬉しかったです。次も面白い漫画の話ししたいですね。(pome) 楽しかったですね、また宜しくお願いします(soh) pomeさん楽しい話をいっぱいありがとうございました。漫画の話いっぱいしたいですね！ (coela) 北欧のいいメタル教えてください、ぐらいのノリでスタートアップを聞いてしまいました。そしてこの音源は10月に収録したものだったのですが、PfizerやModernaのmRNAワクチンのニュースが出る前に公開するべきでした！！！大変申し訳ございません。未来を読んだことにしてくれませんかね？ここはひとつ。pome劇場第二幕に期待…!!!(tadasu)

Since the arrival of Crispr in 2009, gene editing has made its way into labs. Its groundbreaking importance was acknowledged through the 2020 Nobel Prize in Chemistry. Expanding gene editing for medical treatments, Cellectis focuses its 20 years of experience on developing cancer immunotherapies. Curious to Know More? Cellectis CEO André Choulika explains the technology of allogenic gene editing they invented in this episode of the podcast "A View On."

Cellectis has pioneered the "off-the-shelf" approach to gene editing CAR T-cells to treat cancer and other genetic diseases. Dr. André Choulika discusses how this approach allows treatments to be produced by the thousands from healthy donor cells (versus the patient's own cells), stored long-term, provided to hospitals around the world and given to any patient who is in medical need. Off-the-shelf gene editing marks the next transformative step in medicine, and Cellectis has the first U.S. clinical trials underway now.

Alain Marty, Directeur de la rédaction de CFO Radio.TV, Jacques Potdevin, Président de JPA International, Jean-Yves Bajon, Président et co-fondateur de Smart Tréso, et Richard Fremder, rédacteur en chef adjoint de CFO Radio.TV, reçoivent Eric Dutang, DAF de Cellectis.

Rencontre avec André Choulika, pionnier de l’édition génomique. Il est l’inventeur d’une technologie de modification du génome, fondateur de Cellectis un des fleurons de l’industrie biotech française. En 2016, Vanity Fair le propulse au 22e rang des Français les plus influents au monde.Comment devient-on pionnier de la génomique ? Les technologies d'édition vont elles permettre de faire émerger de nouvelles espèces ? Quelles sont les implications éthiques ? Quelles seront les conséquences de la révolution biotech sur l'économie ? Comment s'y préparer ?#LMVQ #Débat #Controverses #Questions #Futur #Prospective #2040 #ADN #CRISPR/CAS9 #transhumanismePour aller plus loin découvrez les videos de Boma France : https://fr.boma.global.comle livre 33 questions pour préparer demain, par Michel Levy Provençal aux éditions Belin : http://bit.ly/33questionsdemain Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

Andy Scharenberg is Chief Scientific Officer at Casebia. Before joining Casebia, Scharenberg was an attending physician at Seattle Children’s Hospital and Principal Investigator in the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. In addition, he served as Co-Director of the Program for Cell and Gene Therapy at Seattle Children’s Hospital, a professor in the Department of Pediatrics and adjunct professor in the Department of Immunology at the University of Washington School of Medicine, and a member of the Transplantation Biology Consortium Program at Fred Hutchinson Cancer Research Center. As Chief Scientific Officer at Cellectis, Scharenberg helped implement a gene-editing partnership with Pfizer. He earned his Bachelor of Science in biochemistry from Indiana University and his medical degree from the University of North Carolina School of Medicine.

CAR T therapy is becoming a hot area of early clinical trials for multiple myeloma patients, but most are personally customized for each patient. A company called Cellectis has developed an off-the-shelf CAR T that every patient can use. Instead of being an "autologous" CAR T treatment (where you use your own cells), this is also called an "allogeneic" CAR T, or a "donor"CAR T. Many of the current CAR T therapies are going after a target called b-cell maturation antigen (BCMA). This It is going after a different target called CS1/SLAMF7. Learn more about this new treatment (called UCARTCS1) from David Siegel, MD, PhD of Hackensack University / John Theurer Cancer Center and how it will be used in early myeloma clinical trials.  Thanks to our episode sponsor: Celgene Corporation

This week, the P4A team are podcasting from the World Orphan Drug Congress in Washington D.C. We speak to André Choulika, Chairman and CEO of Cellectis on the challenges of commercializing a CAR-T cell product and ethical concerns surrounding it, and Anna Bucsics from the Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) on their work supporting new biotech entrepreneurs. Presenter: Joanna Fernandes Contributors: André Choulika, Chairman and CEO of Cellectis; Anna Bucsics, Project Advisor to MoCA and Sophie Schmitz, Managing Partner, P4A Producer: Aparna Krishnan

La modification de l’ADN est-elle toujours un fantasme ? Président et directeur de Cellectis, André Choulika est l’un des pionniers de l’analyse et des applications des méganucléases visant à modifier les génomes complexes.➡️ En savoir plus sur https://fr.boma.global Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

China’s 3SBio gains a North American through its $290 million purchase of Canada’s Therapure Biopharma Marck’s cladribine tablet Mavenclad achieves sustained control of relapsing multiple sclerosis. A patient enrolled in a CAR-T trial dies. I’m Nestor Arellano. And these are the stories we’ll discuss today on the Biotechnology Focus Podcast. But first, let’s talk about the future of Canada’s life science workplace and workforce +++++ What are the things that employees in Canada’s life science industry value about their workplace? What is it about their organization that keep life science professionals and workers engage and productive each day? How can you, as an employer attract and retain great talent? These are just some of the crucial questions many operators and owners of Canadian life science companies face as they work to grow their business. The key to finding the answers to these questions is data. And the best way to get that data is through the ongoing Biotechnology Focus, Stratford Managers Corporation, and BioTalent Canada nationwide 2017 Life Science Workplace Survey. The poll is one of the most comprehensive attempts to take the pulse Canada’s life science workplace environment. The findings of the survey will provide life science organizations across the country a critical guide on what areas to focus on in order to enhance their operations and relationships with their workers. Don’t miss this chance. There’s still time to take part in the poll. All you have to do is head over to Surveymonkey.com/r/biotechEOS and spend a few minutes taking the poll. Remember that’s surveymonkey.com/r/biotechEOS. Do the survey now and have your say counted. ++++ Early this month, Chinese biotech firm 3SBio Inc., shelled out $290 million For Mississauga, ont’s biologics manufacturer Therapure Biophrama. 3SBio is focused on oncology, nephrology and auto-immune diseases. It has been slowly extending its reach out of its Shenyang headquarters in north China. By purchasing Therapure, 3SBio has effectively put its North American expansion plans into high gear. “3SBio’s global expansion strategy is now on fast track,” according to Dr. Jing Lou, chairman of 3SBio He called the purchase “a key milestone of the global expansion strategy” of his business. The acquisition integrates 3SBio’s mammalian cell culture capabilities and Therapure’s downstream purification and plasma source technologies. This also combines the production capacity of the Chinese company’s recently acquired stakes in Sunshine Guojian Pharmaceutical and Sirton Pharmaceuticals SpA with Therapure’s operations. More than 340 biologics professionals in North America focusing on operations and management, market development, R&D, and manufacturing are expected to join 3SBio. 3SBio will also get certain rights to Therapure’s plasma production and technology, according to the Canadian company. Therapure’s CDMO business will continue to operate under the Therapure brand and be led by Therapure’s CEO Nick Green and the current senior management team at its manufacturing facilities located in Mississauga. +++++ Merck’s Mavenclad branded cladribine tablets for the treatment of highly active relapsing multiple sclerosis has demonstrated the medication a achieve sustained control of the disease over four years with a maximum of only 20 days of oral treatment. The trial, included 806 patients out of 1,184 patients who completed an earlier study. The latest study assessed several clinical efficacy endpoints including annualized relapse rate (ARR) and confirmed three-month Expanded Disability Status Scale (EDSS) progression. ++++ CAR-T therapy has been getting a lot of attention recently. Earlier this month, the FDA gave the green light to Novartis’ CAR-T therapy which uses a patient’s own immune cells to destroy aggressive blood cancer cells. With this method, the patient’s T-cells are collected and sent to a manufacturing centre where they are genetically modified to include a new gene that contains a specific protein (a chimeric antigen receptor or CAR) that directs the T-cells to target and kill leukemia cells that have a specific antigen (CD19) on the surface. French biopharmaceutical firm Cellectis was not a fortunate with its own research. The company’s work on an off-the-shelf CAR-T therapy was placed on hold by the United States Food and Drug Administration following the death of one of the patients enrolled in the company’s clinical trial for the therapy. The hold was placed on both UCART123 ongoing Phase 1 studies, respectively in acute myeloid leukemia (AML) and in blastic plas macy toid dend ritic cell neoplasm (BPDCN). A 78-year-old BPDCN male patient received a dose of CD123-targeting CAR-T UCART 123 on August 16. Nine days later, the patient died. Another patient treated in the study experienced a similar but less severe reaction. The 58-year-old woman with AML was given the same dose of UCART 123 as the BPDCN patient. Now Cellectis has to determine what precautions to take before moving forward with enrolling more BPDCN and AML patients for the two phase 1 trials it plans. The (Data Safety Monitoring Board) has recommended lowering the dose of UCART123 in both studies to 4g over 3 days. The French biopharmaceutical firm is now working closely with the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123. +++++ That’s all the time we have for today. Thank you very much for listening in and I hope you enjoyed our podcast. This is your host Nestor Arellano Inviting you to join us again next week for more biotech news and views on the Biotechnology Focus Podcast.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord: